Developer docs
API playgroundTry for free, no card

Search company profiles

Gradient Denervation Technologies

Full company profile

uuid0002hbr

Namestring
Gradient Denervation Technologies
Legal namestring
Gradient Denervation Technologies
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Gradient Denervation Technologies is a privately held, Paris-based medical device company founded in February 2020 that is developing the Gradient™ Denervation System, a minimally invasive, ultrasound-based catheter for pulmonary artery denervation (PADN). The device is designed to ablate nerves around the pulmonary artery using therapeutic ultrasound energy in a percutaneous procedure, with the goal of down-regulating sympathetic activity in the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures. The catheter platform was purpose-built specifically for pulmonary artery anatomy and is built on intellectual property developed at Stanford University by clinicians Dr. Swami Gnanashanmugam and Dr. Jeffrey Feinstein through the Stanford Biodesign Program.

The company targets WHO Group 2 Pulmonary Hypertension — patients with elevated pulmonary vascular resistance due to left-sided heart disease — an indication in which an estimated two-thirds of heart failure patients globally are affected and for which there are currently no approved drug or device therapies in the United States. Gradient has progressed through first-in-human clinical work at Helsicore in Georgia (June 2023), FDA approval of its PreVail-PH2 Early Feasibility Study, first US patient enrollment at Duke University Hospital (March 2024), FDA approval to expand the study (October 2024), FDA Breakthrough Device Designation (May 2025), and FDA TAP Pilot acceptance (June 2025).

The business model is currently pre-revenue: the device is for investigational use only and is not approved for commercial use anywhere in the world. Upon regulatory approval, revenue is expected to be generated through hardware sales of the catheter system to hospitals and academic medical centers via a direct enterprise field-sales motion targeting heart failure specialists. The company operates from Suresnes, France (headquarters) and Maple Grove, Minnesota (US subsidiary Gradient Therapeutics, Inc.), has 11-50 employees, and has raised approximately €17.5M to date across a €3.5M seed (September 2020, Sofinnova MD Start III) and a €14M Series A (September 2023, led by Asabys Partners with Thuja Capital and Sofinnova Partners).

Short descriptiontext

Gradient Denervation Technologies is a Paris-based medical device company developing an ultrasound-based catheter system for pulmonary artery denervation to treat WHO Group 2 pulmonary hypertension in heart failure patients. The device is investigational-only and pre-revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pulmonary artery denervation, ultrasound catheter system, pulmonary hypertension treatment, percutaneous medical device, cardiovascular interventional device
Industry1 code
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Interventional Cardiology Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Pre-revenue company. The Gradient Denervation System is for investigational use only and is not approved for commercial use anywhere in the world. Revenue will be generated through medical device sales upon regulatory approval.

gradientdenervation.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Gradient Denervation Technologies is developing the Gradient Denervation System, a novel ultrasound-based catheter device that performs pulmonary artery denervation (PADN) to treat pulmonary hypertension, particularly in heart failure patients with WHO Group 2 PH. The minimally invasive, percutaneous device ablates nerves around the pulmonary artery using therapeutic ultrasound energy to reduce vascular resistance and lower pulmonary pressures. The device is for investigational use only and is not yet approved for commercial sale anywhere in the world.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Two-thirds of heart failure patients have pulmonary hypertension leading to increased mortality and hospitalization risk
+1 more record
Product overview1 text field

Gradient Denervation Technologies offers a single unified product: the Gradient™ Denervation System, an ultrasound-based catheter device designed for pulmonary artery denervation (PADN) to treat pulmonary hypertension, particularly in heart failure patients with WHO Group 2 Pulmonary Hypertension. The device uses therapeutic ultrasound energy to ablate nerves around the pulmonary artery in a minimally invasive procedure, targeting the sympathetic nervous system's input into the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures. The company is currently conducting clinical trials (PreVail-PH2 Early Feasibility Study) and the device is for investigational use only, not approved for commercial use.

Product and service1 record
1Gradient Denervation System
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-22
Description

First US patient enrolled in the PreVail-PH2 Early Feasibility Study at Duke University Hospital in Durham, NC. Dr. Marat Fudim and Dr. Richard Krasuski are leading investigators in the FDA-approved study.

2Helsicore (Israeli-Georgian Medical Center)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-01
Description

First-in-human clinical study conducted at Helsicore in Tbilisi, Georgia. Dr. Irakli Gogogorishvili performed the initial procedure. The center was selected for bringing the pulmonary artery denervation therapy to patients for the first time.

gradientdenervation.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

SoniVie is an Israeli medical device company developing the TIVUS ultrasound-based system for pulmonary artery denervation (PADN) to treat pulmonary hypertension. It is Gradient's most direct competitor, employing a similar ultrasound-based minimally invasive catheter approach in the same clinical indication.

2Aria CV
TypeDirect peer
Description

Aria CV is developing an implantable device to treat pulmonary hypertension by restoring elastic recoil in the pulmonary artery. It targets the same WHO Group 1 and 2 PH patient population as Gradient, with a complementary but directly competing interventional approach.

TypeDirect peer
Description

Pulnovo Medical is a Chinese medtech company developing a radiofrequency-based pulmonary artery denervation (PADN) system for pulmonary hypertension. It directly competes with Gradient in the PADN category, though it uses RF rather than ultrasound energy.

TypeBroad incumbent
Description

United Therapeutics is an established biopharmaceutical company with a broad pulmonary hypertension drug franchise (Tyvaso, Remodulin, Orenitram). It represents the dominant incumbent treating PH pharmacologically, against which any device therapy like Gradient's must compete.

5Johnson & Johnson (Actelion)
TypeBroad incumbent
Description

Johnson & Johnson, through its Janssen/Actelion franchise, markets leading pulmonary arterial hypertension therapies (Opsumit, Tracleer, Uptravi). As a broad incumbent in PH, J&J is a potential strategic acquirer of device-based PH therapies like Gradient's PADN system.

TypeBroad incumbent
Description

Bayer markets Adempas (riociguat), the only FDA-approved drug for chronic thromboembolic pulmonary hypertension (WHO Group 4) and PAH. As a major cardiovascular pharma, Bayer is both a competitor for PH treatment share and a potential strategic acquirer.

TypeEmerging player
Description

Recor Medical is developing the Paradise ultrasound renal denervation system for hypertension, with pivotal data in progress. Recor shares Gradient's ultrasound denervation modality and could plausibly pivot its catheter platform to PADN if its renal indication succeeds.

TypeBroad incumbent
Description

Medtronic markets the Symplicity renal denervation system and is the dominant incumbent in catheter-based denervation. With its strong interventional cardiology, heart failure, and pulmonary vascular portfolio, Medtronic is a potential strategic acquirer or competitor in the PADN space.

TypeBroad incumbent
Description

Edwards Lifesciences is a leading structural heart and critical care medical device company. Stanton Rowe (Gradient board member) was Edwards' former CSO and co-founded Percutaneous Valve Technologies (acquired by Edwards). Edwards is a logical strategic acquirer for catheter-based cardiovascular innovations like PADN.

TypeEmerging player
Description

Shockwave Medical developed intravascular lithotripsy for calcified coronary and peripheral artery disease, and was acquired by Johnson & Johnson. Shockwave shares the catheter-based intravascular energy delivery model and potential cardiovascular acquirer/strategic partner profile relevant to Gradient's commercialization path.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gradient Denervation Technologies

Interventional Cardiology Medical Devicesgradientdenervation.com

Gradient Denervation Technologies is a Paris-based medical device company developing an ultrasound-based catheter system for pulmonary artery denervation to treat WHO Group 2 pulmonary hypertension in heart failure patients. The device is investigational-only and pre-revenue.

What Gradient Denervation Technologies does

Gradient Denervation Technologies is a privately held, Paris-based medical device company founded in February 2020 that is developing the Gradient™ Denervation System, a minimally invasive, ultrasound-based catheter for pulmonary artery denervation (PADN). The device is designed to ablate nerves around the pulmonary artery using therapeutic ultrasound energy in a percutaneous procedure, with the goal of down-regulating sympathetic activity in the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures. The catheter platform was purpose-built specifically for pulmonary artery anatomy and is built on intellectual property developed at Stanford University by clinicians Dr. Swami Gnanashanmugam and Dr. Jeffrey Feinstein through the Stanford Biodesign Program.

The company targets WHO Group 2 Pulmonary Hypertension — patients with elevated pulmonary vascular resistance due to left-sided heart disease — an indication in which an estimated two-thirds of heart failure patients globally are affected and for which there are currently no approved drug or device therapies in the United States. Gradient has progressed through first-in-human clinical work at Helsicore in Georgia (June 2023), FDA approval of its PreVail-PH2 Early Feasibility Study, first US patient enrollment at Duke University Hospital (March 2024), FDA approval to expand the study (October 2024), FDA Breakthrough Device Designation (May 2025), and FDA TAP Pilot acceptance (June 2025).

The business model is currently pre-revenue: the device is for investigational use only and is not approved for commercial use anywhere in the world. Upon regulatory approval, revenue is expected to be generated through hardware sales of the catheter system to hospitals and academic medical centers via a direct enterprise field-sales motion targeting heart failure specialists. The company operates from Suresnes, France (headquarters) and Maple Grove, Minnesota (US subsidiary Gradient Therapeutics, Inc.), has 11-50 employees, and has raised approximately €17.5M to date across a €3.5M seed (September 2020, Sofinnova MD Start III) and a €14M Series A (September 2023, led by Asabys Partners with Thuja Capital and Sofinnova Partners).

Gradient Denervation Technologies firmographics

Firmographics
Name
Gradient Denervation Technologies
Legal name
Gradient Denervation Technologies
Website
https://gradientdenervation.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Gradient Denervation Technologies is a Paris-based medical device company developing an ultrasound-based catheter system for pulmonary artery denervation to treat WHO Group 2 pulmonary hypertension in heart failure patients. The device is investigational-only and pre-revenue.
Ownership category
akta.pro rank

Gradient Denervation Technologies industry classification

Industry
Product category
Interventional Cardiology Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Pulmonary artery denervation
  • Ultrasound catheter system
  • Pulmonary hypertension treatment
  • Percutaneous medical device
  • Cardiovascular interventional device

Where Gradient Denervation Technologies is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Gradient Denervation Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Pre-revenue company. The Gradient Denervation System is for investigational use only and is not approved for commercial use anywhere in the world. Revenue will be generated through medical device sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Gradient Denervation Technologies product offering

Product offering

Core offering

Gradient Denervation Technologies is developing the Gradient Denervation System, a novel ultrasound-based catheter device that performs pulmonary artery denervation (PADN) to treat pulmonary hypertension, particularly in heart failure patients with WHO Group 2 PH. The minimally invasive, percutaneous device ablates nerves around the pulmonary artery using therapeutic ultrasound energy to reduce vascular resistance and lower pulmonary pressures. The device is for investigational use only and is not yet approved for commercial sale anywhere in the world.

Product overview

Gradient Denervation Technologies offers a single unified product: the Gradient™ Denervation System, an ultrasound-based catheter device designed for pulmonary artery denervation (PADN) to treat pulmonary hypertension, particularly in heart failure patients with WHO Group 2 Pulmonary Hypertension. The device uses therapeutic ultrasound energy to ablate nerves around the pulmonary artery in a minimally invasive procedure, targeting the sympathetic nervous system's input into the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures. The company is currently conducting clinical trials (PreVail-PH2 Early Feasibility Study) and the device is for investigational use only, not approved for commercial use.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gradient Denervation System

Quantifiable outcome

  • Two-thirds of heart failure patients have pulmonary hypertension leading to increased mortality and hospitalization risk
  • +1 more outcomes

Companies that use Gradient Denervation Technologies

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Gradient Denervation Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Gradient Denervation Technologies partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Duke University HospitalcoreStrategic or Co-development Partner · 22 October 2024First US patient enrolled in the PreVail-PH2 Early Feasibility Study at Duke University Hospital in Durham, NC. Dr. Marat Fudim and Dr. Richard Krasuski are leading investigators in the FDA-approved study.
  • Helsicore (Israeli-Georgian Medical Center)coreStrategic or Co-development Partner · 1 June 2023First-in-human clinical study conducted at Helsicore in Tbilisi, Georgia. Dr. Irakli Gogogorishvili performed the initial procedure. The center was selected for bringing the pulmonary artery denervation therapy to patients for the first time.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Gradient Denervation Technologies competitors and assessment

Company assessment

Direct peers

  • SoniVie: SoniVie is an Israeli medical device company developing the TIVUS ultrasound-based system for pulmonary artery denervation (PADN) to treat pulmonary hypertension. It is Gradient's most direct competitor, employing a similar ultrasound-based minimally invasive catheter approach in the same clinical indication.
  • Aria CV: Aria CV is developing an implantable device to treat pulmonary hypertension by restoring elastic recoil in the pulmonary artery. It targets the same WHO Group 1 and 2 PH patient population as Gradient, with a complementary but directly competing interventional approach.
  • Pulnovo Medical: Pulnovo Medical is a Chinese medtech company developing a radiofrequency-based pulmonary artery denervation (PADN) system for pulmonary hypertension. It directly competes with Gradient in the PADN category, though it uses RF rather than ultrasound energy.

Broad incumbents

  • United Therapeutics: United Therapeutics is an established biopharmaceutical company with a broad pulmonary hypertension drug franchise (Tyvaso, Remodulin, Orenitram). It represents the dominant incumbent treating PH pharmacologically, against which any device therapy like Gradient's must compete.
  • Johnson & Johnson (Actelion): Johnson & Johnson, through its Janssen/Actelion franchise, markets leading pulmonary arterial hypertension therapies (Opsumit, Tracleer, Uptravi). As a broad incumbent in PH, J&J is a potential strategic acquirer of device-based PH therapies like Gradient's PADN system.
  • Bayer (PH Franchise): Bayer markets Adempas (riociguat), the only FDA-approved drug for chronic thromboembolic pulmonary hypertension (WHO Group 4) and PAH. As a major cardiovascular pharma, Bayer is both a competitor for PH treatment share and a potential strategic acquirer.
  • Medtronic: Medtronic markets the Symplicity renal denervation system and is the dominant incumbent in catheter-based denervation. With its strong interventional cardiology, heart failure, and pulmonary vascular portfolio, Medtronic is a potential strategic acquirer or competitor in the PADN space.
  • Edwards Lifesciences: Edwards Lifesciences is a leading structural heart and critical care medical device company. Stanton Rowe (Gradient board member) was Edwards' former CSO and co-founded Percutaneous Valve Technologies (acquired by Edwards). Edwards is a logical strategic acquirer for catheter-based cardiovascular innovations like PADN.

Emerging players

  • Recor Medical: Recor Medical is developing the Paradise ultrasound renal denervation system for hypertension, with pivotal data in progress. Recor shares Gradient's ultrasound denervation modality and could plausibly pivot its catheter platform to PADN if its renal indication succeeds.
  • Shockwave Medical: Shockwave Medical developed intravascular lithotripsy for calcified coronary and peripheral artery disease, and was acquired by Johnson & Johnson. Shockwave shares the catheter-based intravascular energy delivery model and potential cardiovascular acquirer/strategic partner profile relevant to Gradient's commercialization path.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Gradient Denervation Technologies social profiles

Digital presence

Gradient Denervation Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gradient Denervation Technologies leadership team

Management profile

Number of profiles

Profiles12 records

Gradient Denervation Technologies funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gradient Denervation Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gradient Denervation Technologies

What does Gradient Denervation Technologies do?

Gradient Denervation Technologies is developing the Gradient Denervation System, a novel ultrasound-based catheter device that performs pulmonary artery denervation (PADN) to treat pulmonary hypertension, particularly in heart failure patients with WHO Group 2 PH. The minimally invasive, percutaneous device ablates nerves around the pulmonary artery using therapeutic ultrasound energy to reduce vascular resistance and lower pulmonary pressures. The device is for investigational use only and is not yet approved for commercial sale anywhere in the world.

Is Gradient Denervation Technologies a public or private company?

Gradient Denervation Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Gradient Denervation Technologies founded?

Gradient Denervation Technologies was founded in 2020. It employs 11 to 50 people.

Where is Gradient Denervation Technologies based?

Gradient Denervation Technologies is headquartered in Paris, France, in the Europe region.

How does Gradient Denervation Technologies make money?

One revenue line is on record: medical Device Sales.

Who are Gradient Denervation Technologies's main competitors?

Direct peers on record are SoniVie, Aria CV and Pulnovo Medical. Broad incumbents are United Therapeutics, Johnson & Johnson (Actelion), Bayer (PH Franchise), Medtronic and Edwards Lifesciences. Emerging players are Recor Medical and Shockwave Medical.

Does Gradient Denervation Technologies have an API?

No public API is recorded for Gradient Denervation Technologies.

What industry is Gradient Denervation Technologies in?

Gradient Denervation Technologies's product category is Interventional Cardiology Medical Devices. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireGradient Denervation Technologies Announces Acceptance intoGradient Denervation Technologies was accepted into the FDA's TAP Pilot for its novel device treating pulmonary hypertension. The company also received Breakthrough Device Designation. The TAP Pilot will enable early FDA interactions and strategic advice to accelerate development.GlobeNewswireGradient Denervation Technologies Announces FDA Breakthrough Designation for Pulmonary Artery Denervation SystemGradient Denervation Technologies received FDA Breakthrough Device Designation for its pulmonary artery denervation system, which uses therapeutic ultrasound to ablate nerves around the pulmonary artery. The system targets pulmonary hypertension and heart failure, with no approved therapies in the U.S. for this group. The company is focused on completing its early feasibility study.GlobeNewswireGradient Denervation Technologies Appoints Stanton Rowe to Board of Directors and Receives FDA Approval to Expand Early Feasibility StudyGradient Denervation Technologies appointed Stanton Rowe to its board and received FDA approval to expand its PreVail-PH2 Early Feasibility Study. The study enrolls patients with WHO Group 2 pulmonary hypertension at US centers. The company's ultrasound-based catheter system is investigational and not approved for commercial use.YahooGradient Denervation Technologies Appoints Stanton Rowe to Board of Directors and Receives FDA Approval to Expand Early Feasibility StudyGradient Denervation Technologies appointed Stanton Rowe to its board and received FDA approval to expand its PreVail-PH2 Early Feasibility Study. The study is enrolling patients with WHO Group 2 pulmonary hypertension at US centers. The company's ultrasound-based catheter system is investigational.MassDeviceGradient Denervation raises $15M Series A for catheter techGradient Denervation Technologies closed a $15 million Series A financing round to support the clinical development of its ultrasound-based catheter for treating pulmonary hypertension. The round was led by Asabys Partners, with participation from Thuja Capital and Sofinnova Partners.FinSMEsGradient Denervation Technologies Closes €14M Series A FundingGradient Denervation Technologies, a Paris-based medical device company for pulmonary hypertension, raised €14M in Series A funding led by Asabys Partners. The funds will support clinical development of its ultrasound-based catheter device, which is investigational and not approved for commercial use.BioSpaceGradient Denervation Technologies closes €14m Series A led by Sabadell AsabysGradient Denervation Technologies, a Paris-based medical device company developing an ultrasound-based catheter for pulmonary hypertension, closed a €14 million Series A round led by Asabys Partners through its Sabadell Asabys II fund. Thuja Capital and founding investor Sofinnova Partners joined, with funds supporting clinical development of the investigational device, initially targeting Group 2 heart failure patients.Empresas de Capital Riesgo en EspaGradient Denervation Technologies closes €14m Series A led by Sabadell AsabysGradient Denervation Technologies closed a €14 million Series A financing round led by Sabadell Asabys II, with participation from Thuja Capital and Sofinnova Partners. The funds will support the clinical development of Gradient's ultrasound-based catheter device for treating pulmonary hypertension. This investment follows the company's initiation of a first-in-human clinical study earlier in the year.